AMRN

Amarin Corp. PLC\UK

NasdaqAdd to watchlist

Healthcare · Drug Manufacturers—General

$13.63

−$0.24−1.73%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

Aug 24, 2026$13.63

−$0.21−1.52%over 1M

Session

Day range16% of range

$13.58$13.90

Fundamentals

Visualize fundamentals and more

Market cap: 5.68B
P/E ratio: -

Revenue grew −6.55% in FY2025, +15.41% slower than its sector. The median across Healthcare companies this platform tracks is +8.87%.

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 54
dropped: 42
re-drafted: 65

Out of 314 passages in this year’s Item 1A.

New this year

• in the U.S., we compete with and may face increasing competition from generic drug companies, non-prescription competition omega-3 fatty acids and consumer substitution, and our revenues and results of operations could continue to be materially and …

95 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Litigation
Tax
China
Patent expiry
The Middle East
Product recalls

And 16 more.

FDA approval
Recordati has as exclusive license to develop and commercialize VASCEPA in 59 countries, focused in Europe, for uses that are currently commercialized and under development based on our REDUCE-IT clinical trials. We will be eligible to receive sales-based …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

13 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Amarin Corp. PLC\UK investor relations

What AMRN has filed with the SEC. This is not Amarin Corp. PLC\UK’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Amarin Corp. PLC\UK

Also filed under Drug Manufacturers, ranked by how closely they sit beside AMRN.

LLYELI LILLY & Cocompare with AMRN
JNJJohnson & Johnsoncompare with AMRN
AMGNAmgen Inc.

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Litigation
Tax
China
Patent expiry
The Middle East
Product recalls

And 16 more.

FDA approval
Recordati has as exclusive license to develop and commercialize VASCEPA in 59 countries, focused in Europe, for uses that are currently commercialized and under development based on our REDUCE-IT clinical trials. We will be eligible to receive sales-based …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

MRKMerck & Co., Inc.compare with AMRN

BMYBristol Myers Squibb Co.compare with AMRN

Ask about Amarin Corp. PLC\UK

The assistant answers from what AMRN has actually filed: 17 annual reports filed with the SEC, 52 Form 4 filings from the last year and 1 fund that holds it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from AMRN's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Amarin Corp. PLC\UK each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Amarin Corp. PLC\UK

Be told the moment a AMRN insider trades
Put Amarin Corp. PLC\UK on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Amarin Corp. PLC\UK's income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Amarin Corp. PLC\UK's fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 54
dropped: 42
re-drafted: 65

Out of 314 passages in this year’s Item 1A.

New this year

• in the U.S., we compete with and may face increasing competition from generic drug companies, non-prescription competition omega-3 fatty acids and consumer substitution, and our revenues and results of operations could continue to be materially and …

95 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add